AUTL - Autolus Therapeutics plc

QQQ $ 615.11 $ -4.04 (-0.65 %)

DIA $ 470.25 $ 0.57 (0.12 %)

SPY $ 672.36 $ -0.79 (-0.12 %)

TLT $ 90.13 $ 0.15 (0.17 %)

GLD $ 362.19 $ -1.27 (-0.35 %)

Previous Close

$ 1.41

Open

$ 1.49

Bid

$ 1.42 x 599

Ask

$ 1.53 x 200

Day's Range

$ 1.40 - $ 1.54

52 Week Range

$ 1.11 - $ 4.12

Volume

1,971,205

Average Volume

Market Cap

375.26M

Beta (5Y Monthly)

$ 1.51

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2025	06-30-2025	10-Q
2	05-08-2025	03-31-2025	10-Q
3	03-20-2025	12-31-2024	10-K
4	11-12-2024	09-30-2024	10-Q
5	08-08-2024	06-30-2024	10-Q
6	05-17-2024	03-31-2024	10-Q
7	03-21-2024	12-31-2023	10-K
8	11-09-2023	09-30-2023	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Needham Reiterates Buy on Autolus Therapeu...
11/03/2025 17:14:31

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.

Autolus' Obe-cel Shows 83% Remission Rate ...
10/27/2025 11:10:24

Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and deliv...

Autolus Therapeutics Doses First Patient I...
10/20/2025 11:09:39

Needham Reiterates Buy on Autolus Therapeu...
10/20/2025 09:41:48

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.

Autolus To Present Early Data From CARLYSL...
09/16/2025 12:19:30

Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and deliv...

Wells Fargo Maintains Overweight on Autolu...
08/13/2025 12:50:02

Wells Fargo analyst Yanan Zhu maintains Autolus Therapeutics (NASDAQ:AUTL) with a Overweight and lowers the price target fro...

Autolus Therapeutics Q2 EPS $(0.18) Beats ...
08/12/2025 11:05:08

Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of ...

Earnings Scheduled For August 12, 2025
08/12/2025 08:32:28

Needham Reiterates Buy on Autolus Therapeu...
07/21/2025 13:59:51

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.

$autolus-therapeutics-aucatzyl-granted-european-marketing-authorization-for-relapsed-for-refractory-b-cell-precursor-acute-lymphoblastic-leukemia-in-adult-patients$

Autolus Therapeutics' AUCATZYL Granted Eur...
07/21/2025 11:03:38

fda-eases-access-to-life-saving-gene-therapies-for-blood-cancers

FDA Eases Access To Life-Saving Gene Thera...
06/30/2025 12:36:39

FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and a...

What 4 Analyst Ratings Have To Say About A...
06/12/2025 19:01:36

Needham Reiterates Buy on Autolus Therapeu...
06/12/2025 16:01:34

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.

Autolus Therapeutics Reports 42.6-Month Me...
06/12/2025 07:33:35

Median duration of response in FELIX study now 42.6 months after an additional 11 months of follow upMore than half of patients...

$autolus-therapeutics-announces-positive-chmp-opinion-for-obecabtagene-autoleucel-for-adult-patients-with-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia$

Autolus Therapeutics Announces Positive CH...
05/23/2025 12:33:10

Positive CHMP opinion based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demo...

Autolus Therapeutics Presents Clinical Dat...
05/14/2025 13:35:10

Autolus Therapeutics Q1 EPS $(0.26), Inline
05/08/2025 11:06:18

Earnings Scheduled For May 8, 2025
05/08/2025 08:33:13

$mhra-grants-conditional-marketing-authorisation-for-autolus-therapeutics-aucatzyl-for-treatment-of-adult-patients-with-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia$

MHRA Grants Conditional Marketing Authoris...
04/25/2025 16:10:01

UK Medicines and Healthcare products Regulatory Agency (MHRA) authorisation based on FELIX clinical trial of obecabtagene autol...

Needham Reiterates Buy on Autolus Therapeu...
04/10/2025 11:18:17

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.